Ki-67 index

What it is

Ki-67 index is the percentage of tumour cells staining positive for Ki-67, a proliferation marker, usually reported as a percent. In practice, the key number is the percentage of positive tumour cells, such as 10%, 20%, or 40%, because higher values generally mean the cancer is dividing more quickly.

Ki-67 is a nuclear protein present in cells that are actively moving through the cell cycle, but not in resting cells. Pathologists usually measure it by immunohistochemistry, or IHC, on a biopsy or surgery specimen. The result is often called the Ki-67 proliferation index, Ki-67 labelling index, or Ki67 index.

Ki-67 is most commonly discussed in breast cancer, but it is also used in several other tumours and some lymphomas. It is a biomarker of cell proliferation, not a diagnosis by itself. A high Ki-67 index can support the impression that a tumour is biologically more aggressive, but the meaning depends on the cancer type, the lab method, and the clinical context.

Term	Meaning
Ki-67 positive cell	A tumour cell whose nucleus stains for Ki-67 on IHC
Ki-67 index	Percent of tumour cells that are Ki-67 positive
Low vs high Ki-67	Relative categories that vary by cancer type and guideline

How it works

Ki-67 reflects how many cells are actively proliferating. Because it is expressed during active phases of the cell cycle and absent in resting cells, it acts as a rough snapshot of tumour growth fraction. A tumour with a higher Ki-67 index has a larger proportion of cells in active division.

The test is done on tissue, not blood. A pathologist stains the sample with an antibody against Ki-67 and then estimates or counts the proportion of stained tumour nuclei among the total tumour cells examined. Some laboratories use manual counting, while others use digital image analysis. The exact approach matters because different counting methods can produce different percentages.

This is one reason Ki-67 can be useful but imperfect. Two labs may not always produce exactly the same result from similar samples, especially when the staining is patchy, the specimen is small, or the tumour has "hot spots" with more proliferation than other areas.

Evidence and uses

Ki-67 is mainly used as a prognostic biomarker, and in some settings it also helps with treatment decisions. The strongest routine clinical use is in breast cancer, especially hormone receptor-positive, HER2-negative early breast cancer, where Ki-67 may add information alongside tumour size, grade, lymph node status, ER, PR, and HER2.

In breast cancer, higher Ki-67 levels are generally associated with worse outcomes and more aggressive disease biology. Reviews and meta-analyses have found that higher cutoffs such as 20%, 25%, 30%, or 40% can correlate with poorer recurrence-free or overall survival in different subgroups. However, there is no single universal cutoff that works for every patient or every lab.

Common clinical uses include:

1. Breast cancer prognosis: Higher Ki-67 often suggests a faster-growing tumour.
2. Subtype support: In ER-positive/HER2-negative disease, Ki-67 may help distinguish more indolent from more proliferative cancers, though it should not be used alone.
3. Response assessment in neoadjuvant therapy: Changes in Ki-67 after endocrine therapy or chemotherapy can provide information about treatment effect.
4. Other cancers and lymphomas: Ki-67 may carry prognostic value in mantle cell lymphoma and some solid tumours, but interpretation is disease-specific.

A few important points help patients read the result correctly:

• Higher is not always "worse" in a simple way. Some fast-growing tumours may also be more sensitive to chemotherapy.
• Cutoffs vary. One report may call 15% low, another may use 20% or 25% as a clinically relevant threshold.
• It is not a stand-alone marker. Doctors interpret it with pathology grade, stage, receptor status, imaging, and overall health.

In India, Ki-67 is widely available in pathology laboratories as part of IHC panels for breast cancer and some other tumours. Access is often better than access to more expensive multigene assays, so it may be used as one piece of decision-making where genomic testing is not feasible. Even so, the same caution applies: pre-analytic and lab-to-lab variation can affect the number.

Diagnosis / how it's measured

Ki-67 is measured on tumour tissue by IHC. The pathology report usually gives a percentage, for example, "Ki-67: 18%" or "Ki-67 labelling index: 35%." That percentage represents the proportion of tumour cells that stained positive.

Typical steps are:

1. A biopsy or surgical specimen is fixed and processed.
2. The lab stains the tissue with an antibody to Ki-67.
3. The pathologist counts positive tumour nuclei in selected areas.
4. The result is reported as a percentage.

Factors that can affect the result include:

Factor	Why it matters
Tissue fixation time	Poor fixation can alter staining quality
Small biopsy sample	May not represent the whole tumour
Tumour heterogeneity	Some areas proliferate faster than others
Counting method	Manual and digital methods may differ
Lab protocol	Antibody clone, staining platform, and scoring rules vary

Because of these issues, Ki-67 has known reproducibility problems. International working groups have tried to standardise scoring, but agreement is still better at very low and very high values than in the intermediate range. If a treatment decision depends heavily on a borderline Ki-67 result, clinicians may weigh other pathology features carefully or, in selected cases, consider repeat review.

When to see a clinician

You should discuss a Ki-67 result with your treating oncologist or pathologist if it appears on a biopsy or surgery report, especially for breast cancer. The number is meaningful only when matched to the exact cancer type, stage, receptor profile, and treatment plan.

Ask for clarification if:

• the report gives a percentage but no interpretation
• the result seems to conflict with tumour grade or other markers
• treatment decisions such as chemotherapy, endocrine therapy, or neoadjuvant treatment are being considered
• the sample was very small or taken after treatment, which can change interpretation

A pathology second review can be reasonable when the result is borderline and may change management.

Limitations and open questions

Ki-67 is useful, but it has limits. The biggest problem is variability: different laboratories, antibodies, scoring methods, and tumour areas can produce different percentages. This is why a single cutoff cannot be applied reliably across all cancers and all settings.

Evidence is strongest in breast cancer, but even there, experts do not treat Ki-67 as a perfect decision tool on its own. Intermediate values are the hardest to interpret. Very low and very high values are usually more informative than a result near the middle.

Another open question is how best to integrate Ki-67 with genomic assays, digital pathology, and newer predictive markers. Research continues on whether standardised digital scoring can improve reproducibility and whether dynamic changes in Ki-67 during treatment should guide therapy more often.

For patients, the practical takeaway is simple: Ki-67 is a helpful marker of how quickly a tumour is growing, but it is only one part of the pathology picture.